Drug Trial Radar · NCT05280509
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jun 9, 2022
Primary completion
Oct 2025
Study completion Apr 2027
Sponsor
- Lead sponsor
- Telios Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
Conditions
- Myelofibrosis
- Primary Myelofibrosis
- Post-PV MF
- Post-ET Myelofibrosis
Interventions
TL-895Drug
TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
RuxolitinibDrug
Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b - Recommended Phase 2 dose of TL-895 in combination with ruxolitinibTime frame: 28 days
- Phase 2 - Spleen Volume Reduction (SVR) at Week 24Time frame: 24 Weeks
Locations
19 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Gabrail Cancer Center
Canton, Ohio · Recruiting
University of Cincinnati (UC)
Cincinnati, Ohio · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
CHU Angers
Angers, France · Recruiting
AP-HM - Hôpital de la Timone
Marseille, France · Recruiting
CHU de Nice - Hopital L'Archet II
Nice, France · Recruiting
Hôpital Saint Louis - AP-HP
Paris, France · Recruiting
Centre Hospitalier Lyon Sud
Pierre-Bénite, France · Recruiting
Marien Hospital Duesseldorf
Düsseldorf, Germany · Recruiting
Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall
Halle, Germany · Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
Bologna, Italy · Recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milan, Italy · Recruiting
Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia
Perugia, Italy · Recruiting
Pratia Onkologia Katowice
Katowice, Poland · Recruiting
Hospital Universitari Arnau de Vilanova
Lleida, Spain · Recruiting
Hospital Universitario Ramon y Cajal
Madrid, Spain · Recruiting
Hospital Universitario Virgen de la Victoria
Málaga, Spain · Recruiting
Hospital Quironsalud de Zaragoza
Zaragoza, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.